Head-to-head evidence
Blixeprodil vs Onfasprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
Blixeprodil
Developed by Gilgamesh Pharmaceuticals
NCT06309277 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 46 participants, but the primary endpoint was treatment-emergent adverse-event incidence rather than an efficacy endpoint. The registry reports adverse-event counts but no statistical comparison for this primary endpoint, so whether it was met is unclear; the depression-rating result was a statistically significant secondary finding.
Onfasprodil
Developed by Novartis
NCT03756129 · Phase 2 · completed
Participants were randomized and blinded to MIJ821, placebo, or ketamine, but the 70-person study was small and spread across six treatment groups. The clinical primary endpoint was met at 24 hours for both pooled MIJ821 dose groups versus placebo, with statistically significant MADRS score differences, but the limited sample size supports moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Blixeprodil's landscape · Onfasprodil's landscape